Trump drug price deadline prompts pharma firms to announce initiatives, impacting U.S. market with new models.
• Pharma firms announce initiatives before Trump deadline.
• Focus on direct-to-consumer models in the U.S.
• Aims to align U.S. prices with international levels.
Pharmaceutical companies are making last-minute efforts to meet a Trump administration deadline set for 29 September 2025, which demands a reduction in U.S. drug prices. This initiative is part of President Trump’s ‘most-favored nations’ policy, which aims to align U.S. drug prices with those in other countries. In July, Trump sent letters to 17 major pharmaceutical companies, urging them to take action. Read more on STAT.
Among the responses, companies like AstraZeneca and Bristol Myers Squibb have announced new direct-to-consumer models. These models aim to bypass traditional intermediaries such as insurers and pharmacy benefit managers, potentially lowering costs for consumers. However, a White House official noted that these efforts might not fully satisfy the administration’s demands unless they result in price reductions comparable to international levels.
The pharmaceutical industry is under pressure to adapt quickly. The introduction of direct-to-consumer models is seen as a significant shift in strategy, potentially reshaping how medications are distributed in the U.S. market. This move could also influence other companies to adopt similar strategies, increasing competition and potentially benefiting patients through lower prices.
The broader impact of these initiatives remains uncertain. Analysts suggest that while direct-to-consumer models may improve access and reduce some costs, achieving the price reductions demanded by the Trump administration will require more comprehensive changes. The pharmaceutical industry is closely watching these developments, as they could set a precedent for future pricing policies.
For more insights on Market Access, visit our Market Access section.